In last trading session, Sangamo Therapeutics Inc (NASDAQ:SGMO) saw 2.04 million shares changing hands with its beta currently measuring 1.36. Company’s recent per share price level of $0.52 trading at -$0.04 or -6.83% at ring of the bell on the day assigns it a market valuation of $106.72M. That closing price of SGMO’s stock is at a discount of -246.15% from its 52-week high price of $1.80 and is indicating a premium of 44.23% from its 52-week low price of $0.29. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.79 million shares which gives us an average trading volume of 2.35 million if we extend that period to 3-months.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Upright in the red during last session for losing -6.83%, in the last five days SGMO remained trading in the red while hitting it’s week-highest on Thursday, 04/04/24 when the stock touched $0.52 price level, adding 16.32% to its value on the day. Sangamo Therapeutics Inc’s shares saw a change of -3.55% in year-to-date performance and have moved -14.10% in past 5-day. Sangamo Therapeutics Inc (NASDAQ:SGMO) showed a performance of -40.62% in past 30-days. Number of shares sold short was 10.88 million shares which calculate 3.52 days to cover the short interests.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Statistics highlight that Sangamo Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 0.77% of value to its shares in past 6 months, showing an annual growth rate of 8.47% while that of industry is 13.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -275.00% in the current quarter and calculating 78.80% increase in the next quarter. This year revenue growth is estimated to fall -74.00% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $6.65 million for the same. And 6 analysts are in estimates of company making revenue of $8.24 million in the next quarter that will end on Jun 2024. Company posted $157.96 million and $14.83 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -95.80% while estimating it to be -44.40% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.96% during past 5 years.
SGMO Dividends
Sangamo Therapeutics Inc is more likely to be releasing its next quarterly report between March 12 and March 16 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Insiders are in possession of 9.45% of company’s total shares while institution are holding 43.79 percent of that, with stock having share float percentage of 48.36%. Investors also watch the number of corporate investors in a company very closely, which is 43.79% institutions for Sangamo Therapeutics Inc that are currently holding shares of the company. Wasatch Advisors LP is the top institutional holder at SGMO for having 17.05 million shares of worth $22.17 million. And as of Jun 29, 2023, it was holding 9.63% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 15.89 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 8.97% of outstanding shares, having a total worth of $20.66 million.
On the other hand, Wasatch Ultra Growth Fund and Wasatch Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 6.48 million shares of worth $8.42 million or 3.66% of the total outstanding shares. The later fund manager was in possession of 4.44 million shares on Jun 29, 2023, making its stake of worth around $5.77 million in the company or a holder of 2.51% of company’s stock.
